Acrivon Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
ACRV$1.57-0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEM ENTS OF CASH FLOWS
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(80,556) | $(60,388) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 1,006 | 536 |
| Stock-based compensation expense | 14,288 | 11,618 |
| Non-cash operating lease expense | 932 | 778 |
| Net amortization of premiums and accretion of discounts on investments | (3,777) | (3,323) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 237 | 2,110 |
| Accounts payable | (3,586) | 3,609 |
| Accrued expenses and other liabilities | 8,021 | 3,173 |
| Operating lease liabilities | (1,055) | (754) |
| Other assets | (1,179) | — |
| Net cash used in operating activities | (65,669) | (42,641) |
| Cash flows from investing activities: | ||
| Purchases of investments | (202,926) | (56,528) |
| Proceeds from maturities of investments | 153,923 | 108,533 |
| Purchases of property and equipment | (2,768) | (1,288) |
| Net cash (used in) provided by investing activities | (51,771) | 50,717 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock in private placement | 69,997 | — |
| Proceeds from issuance of pre-funded warrants in private placement | 60,003 | — |
| Proceeds from exercise of stock options | 90 | 775 |
| Payments of offering costs | (6,543) | (1,032) |
| Payments of tax withholdings related to vesting of restricted stock units | (2,520) | (1,297) |
| Net cash provided by (used in) financing activities | 121,027 | (1,554) |
| Net increase in cash, cash equivalents, and restricted cash | 3,587 | 6,522 |
| Cash, cash equivalents and restricted cash at beginning of period | 36,429 | 29,907 |
| Cash, cash equivalents and restricted cash at end of period | $40,016 | $36,429 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Purchases of property and equipment included in accounts payable | $17 | $635 |
| Right-of-use assets obtained in exchange for operating lease liability | $56 | $437 |
| Deferred offering costs in accounts payable | $— | $85 |
| Reconciliation of cash, cash equivalents, and restricted cash: | ||
| Cash and cash equivalents | $39,818 | $36,015 |
| Restricted cash | 198 | 414 |
| Total cash, cash equivalents, and restricted cash | $40,016 | $36,429 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.